← Back to Clinical Trials
Recruiting NCT07459062

NCT07459062 Spectral Cancer Tissue Recognition - I

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07459062
Status Recruiting
Phase
Sponsor SPCTR
Condition Margin Assessment
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2026-01-12
Primary Completion 2026-08-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2026-01-12 with a primary completion date of 2026-08-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This analytical performance study aims to validate the SPCTRone system for use in breast conserving surgery of breast cancer patients. By collecting spectral biomarkers and correlating these with the golden standard of histopathological assessment by a pathologist, we aim to train and optimize an AI model that is able to achieve the following outcomes with classifying tissues: * Sensitivity (percentage of classified positive margins of actual positive margins): ≥ 96% CI 95.5-97.5% * Specificity (percentage of classified free margins of actual free margins): 96% CI 95.5-97.5% * Accuracy (total correctly classified margins): ≥ 96% CI 95.5-97.5% * Negative predictive value (amount of true negative - free margins - among the classified negative margins): ≥ 95% CI 94.5-96.5%

Eligibility Criteria

Inclusion Criteria: * Age ≥18 years * Confirmed diagnosis breast cancer for which surgical procedure is needed * Planned for breast conserving surgery Exclusion Criteria: * Person that undergoes breast amputation without confirmed cancer diagnosis

Contact & Investigator

Central Contact

Robin Merjenburgh

✉ robin@spctr.tech

📞 +31681119503

Frequently Asked Questions

Who can join the NCT07459062 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Margin Assessment. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07459062 currently recruiting?

Yes, NCT07459062 is actively recruiting participants. Contact the research team at robin@spctr.tech for enrollment information.

Where is the NCT07459062 trial being conducted?

This trial is being conducted at Groningen, Netherlands, Utrecht, Netherlands.

Who is sponsoring the NCT07459062 clinical trial?

NCT07459062 is sponsored by SPCTR. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology